Significance:
Cancer suppressor p53 is mutated in more than 50% of human cancers of different origin, while its pathway is altered in about 80% of tumors.
This study suggests a therapeutic strategy as to how p53-deficient/deleted or mutant p53 expressing human metastatic cancers can be cured by activating its unmutated or rarely mutated “homologous protein such as TAp63γ” .
Research Findings:
MiRNA-9600, by decreasing the expression of its target genes, it may increase the expression of tumor suppressor TAp63. Thereby, it may inhibit the migration and invasion of metastatic cancer cells.
Therapeutic opportunity:
Given that MiR-9600 may induce the expression of TAp63 in p53-mutated human tumors, pharmacological formulations encompassing “MiRNA-9600 or its activators” may be used to inhibit the progression of p53-mutated invasive metastatic tumors.
Together, this study suggests an MiRNA-based therapy for p53-mutated metastatic human tumors.
Details of the research findings:
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Amount: $100#
Undisclosed information: How MiR-9600 increases the expression of TAp63
#Research cooperation
References:
Web: http://genomediscovery.org or http://newbioideas.com
Citation: Boominathan, Therapeutic insights into “awakening the sleeping angel” in mutant p53-expressing human tumors: MiR-9600 increases the expression of tumor suppressor p53 homologue TAp63 and induces regression of p53-mutated human tumors via down regulation of its target gene, 17/November/2016, 10.27 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org